All In Biotech

NDA 209310 · Intersect Ent INC

Sinuva

Mometasone Furoate · Implantation

Last checked: Nov 20, 2026Latest source record: Jan 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 8, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

251

94 Phase 3, 12 recruiting

FAERS reports

10,454

7,256 serious, 489 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2023.

SINUVA Sinus Implant is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥18 years of age who have had ethmoid sinus surgery. SINUVA Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18years of age who have had ethmoid sinus surgery. ( 1 )

Mechanism: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on inflammation is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 2020 Supplement 3 · Efficacy Label
  • Dec 8, 2017 Original approval · Type 3 - New Dosage Form LabelLetterReview
1 products under this application
  • SINUVA · MOMETASONE FUROATE 1.35MG · IMPLANT, IMPLANTATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.

All 251 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,001
  • drug ineffective925
  • headache916
  • asthma904
  • off label use780
  • cough750
  • fatigue677
  • pruritus640
  • gastrooesophageal reflux disease593
  • nausea563
  • wheezing562
  • hypersensitivity556

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200457
200556
200656
200791
2008150
2009122
2010145
2011143
2012145
201396
2014108
2015168
2016299
2017326
2018764
2019769
2020734
2021982
20221,219
20231,225
20241,019
20251,028
2026752

Recalls

1 FDA enforcement reports for this application.

  • Jan 4, 2023 · Class III · Terminated

    Failed Dissolution Specification; product did not meet the average 24-hour drug release rate (dissolution) specification stability time point at 9 months.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Sinuva (Mometasone Furoate) · HCPCS J7402

2024 spending

$151K

Beneficiaries

56

68 claims

Per beneficiary

$2,688

2024 ASP limit $11.35 per unit

View as table
YearSpending
2020$0
2021$796,228
2022$622,255
2023$320,066
2024$150,533

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 421 on PubMed

Sponsor: Intersect Ent INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.